Eptinezumab is a monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults. Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals.
- Mechanism
- Curator reviewed · 7 references
Eptinezumab is a fully-humanized IgG1 antibody manufactured and designed specifically to bind both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).
Studies since 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after efficacious sumatriptan therapy. Moreover, research has also shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For all these reasons, the binding of CGRP to interfere with its activity was specifically designed to be the form and mechanism of action for eptinezumab. The binding of eptinezumab to natural endogenous CGRP subsequently interferes with its activities, such as its binding to CGRP receptors, for example.
- Primary indication
- Eptinezumab is indicated for the preventive treatment of migraine in adults.Curator reviewed · 1 structured indication
- Formula / weight
- 143000.0 Da
- First approval
- Canada, 2021 · United States, 2020 · European Union, 2022
- Code names
- ALD403 · Lu AG09221
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Eptinezumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account